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Abstract:  
Background & Aims: Proliferating cholangiocytes secrete and respond to 
neuroendocrine hormones including secretin. We investigated whether secretin 
secreted by S cells and cholangiocytes stimulates biliary proliferation in mice. 
 
Methods: Cholestasis was induced in secretin knockout (Sct–/–) and wild-type (control) 
mice by bile-duct ligation (BDL). At days 3 and 7 after BDL, control and Sct–/– mice 
received tail-vein injections of morpholinos against microRNA 125b or let7a. One week 
later, liver tissues and cholangiocytes were collected; immunohistochemical, immnoblot, 
luciferase reporter and real-time PCR assays were performed. Intrahepatic bile duct 
mass (IBDM) and proliferation were measured. Secretin secretion was measured in 
conditioned media from cholangiocytes and S cells, and in serum and bile.  
 
Results: Secretin secretion was increased in supernatants from cholangiocytes and S 
cells and in serum and bile following BDL in control mice. BDL Sct–/– mice had lower 
IBDM, reduced proliferation, and reduced production of vascular endothelial growth 
factor A (VEGFA) and nerve growth factor (NGF) compared with BDL control. BDL and 
control mice given morpholinos against microRNA 125b or let7a had increased IBDM. 
Livers of mice given morpholinos against microRNA 125b had increased expression of 
VEGFA while those treated with morpholinos against microRNA let7a had increased 
expression of NGF. Secretin regulated VEGF and NGF expression that negatively 
correlated with microRNA 125b and let7a levels in liver tissue. 
 
Conclusions: Following liver injury, secretin produced by cholangiocytes and S cells 
reduces microRNA 125b and let7a levels, resulting in upregulation of VEGF and NGF. 
Modulation of cholangiocyte expression of secretin could be a therapeutic approach for 
biliary diseases. 
 
KEYWORDS: Biliary epithelium, cAMP, gastrointestinal hormones, heterogeneity 
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INTRODUCTION 
Cholangiocytes are target cells in cholangiopathies including primary biliary cirrhosis 
(PBC) and primary sclerosing cholangitis (PSC), which are disorders associated with 
dysregulation of the balance between cholangiocyte proliferation/loss.1, 2 The bile duct 
ligated (BDL) model mimics some features of human cholangiopathies.3, 4 In rodents with 
BDL, large but not small cholangiocytes proliferate via activation of cAMP-dependent 
signaling leading to increased large intrahepatic bile duct mass (IBDM).3, 5 The reaction 
of cholangiocytes to injury features a “neuroendocrine-like” trans-differentiation, which 
allows cholangiocytes to secrete a number of peptides and hormones that modulate 
cholangiocyte responses to injury by autocrine/paracrine mechanisms.6-8 
The neuroendocrine hormone secretin is secreted by S cells that are localized primarily 
in the mucosa of the duodenum.9 We have shown that secretin stimulates biliary growth 
by interaction with secretin receptors (SR, expressed only by large cholangiocytes)10 and 
in vivo and in vitro knockout of SR reduces biliary proliferation by downregulating cAMP-
dependent signaling.11 No data exists regarding hepatic expression of secretin and role 
of secretin in the regulation of cholangiocyte growth/damage in biliary diseases.   
MicroRNAs, which are post-transcriptional regulators that bind to complementary 
sequences on the 3’-UTR of target mRNA, alter gene translation and regulate 
hepatobiliary function.12, 13 Following partial hepatectomy, microRNA 181b expression is 
upregulated in cholangiocytes,14 whereas microRNA 125b is downregulated in 
hepatobiliary cancers.13 In a model of cholestasis-associated cholangiocarcinoma, there 
was enhanced expression of microRNA let7a, which targets NF2/Merlin (critical regulator 
of cell proliferation/apoptosis).15 The rationale for studying microRNA 125b and 
microRNA let7a is based on 3’-UTR sequence analysis and prediction algorithms, which 
reveal several microRNAs potentially targeting VEGF and NGF. MicroRNA 125b and 
microRNA let7a, two microRNA isoforms involved in hepatobiliary injury and cellular 
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proliferation,13, 16 were identified as potential upstream microRNAs directly targeting 
VEGF/NGF from our most down-regulated miRNA list after BDL  using combined 
analysis by TargetScan (http://targetscan.org/) and miRBase 
(http://microRNA.sanger.ac.uk/) databases17, and through our most down-regulated 
microRNA list from microRNA microArray profiling data after BDL (show enhanced 
VEGF and NGF expression). 
No information exists regarding mechanisms by which VEGF/NGF mediate secretin’s 
trophic effects in cholangiocytes.11, 18 We have shown that changes in biliary proliferation 
(by administration of VEGF to rats with hepatic artery ligation) were associated with 
changes in secretin-stimulated choleresis.18 However, this study did not demonstrate a 
direct link between secretin and VEGF.  Thus, we performed studies to evaluate if 
secretin stimulates biliary growth by autocrine/paracrine mechanisms through changes 
in microRNA 125b/microRNA let7a expression. 
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Materials and Methods 
Materials  
Reagents were purchased from Sigma Aldrich Co. (St. Louis, MO) unless otherwise 
stated. The normal human intrahepatic cholangiocyte line (HIBEpiC) was purchased 
from ScienCell Research Laboratories (Carlsbad, CA).19 The antibodies used are listed 
in Suppl. File 1.  MicroRNA precursors and anti-microRNA-specific inhibitors of 
microRNA 125b/microRNA let7a along with control microRNA precursors and inhibitors 
were purchased from Ambion (Austin, TX).  pRL-TK microRNA let7a and pRL-TK 
controls were obtained from Addgene (Cambridge, MA) and Promega (Madison, WI), 
respectively. The cAMP EIA kit was purchased from Cayman Chemical (Ann Arbor, MI). 
 
Animal Models  
Animal procedures were performed according to protocols approved by Scott and White 
and Texas A&M HSC IACUC. Secretin (Sct) knockout (KO, Sct-/-) mice were generated 
and characterized as described by us.20 Sct+/+ (wild-type, WT) and Sct-/- mice were 
maintained in a temperature-controlled environment with 12:12-hr light-dark cycles.  We 
used male normal (or sham) and BDL (1 week) WT and Sct -/- mice (~25-30 g) of the N5 
generation (Table 1).  WT mice were purchased from Charles River Laboratories 
(Wilmington, MA).  Since there were no differences in biliary growth between WT and 
Sct -/- mice and corresponding shams, we did not perform experiments on sham animals. 
Liver and body weight and liver to body weight ratio were measured.4 Normal WT mice 
were treated with secretin (2.5 nmoles/kg BW/day) by osmotic minipumps for 1 week.11 
To reduce hepatic expression of microRNA 125b and microRNA let7a, normal or BDL 
WT mice (immediately after surgery)4 were treated by two tail vein injections (one at day 
3 and one at day 7) with Vivo-Morpholino sequences of microRNA 125b 
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(5’CATCACAAGTTAGGGTCTCAGGGAC3’), microRNA let7a 
(5’AACTATACAACCTACTACCTCATCC3’), or mismatched Morpholinos 
(5’CATCAgAAcTTAcGGTCTgAcGGAC3’ for microRNA 125b) or 
(5’AAgTATAgAAgCTAgTAgCTCATCC3’ for microRNA let7a), 30 mg/kg BW.  We have 
previously shown the Vivo-Morpholino approach reduced biliary expression of 
arylalkylamine N-acetyltransferase (enzyme regulating melatonin secretion) in BDL 
rats.21 One week later, liver tissue and cholangiocytes were collected.  In RNA from 
isolated cholangiocytes, we measured the expression of microRNA 125b and microRNA 
let7a by real-time PCR. IBDM and semiquantitative expression of VEGFA and NGF was 
evaluated in liver sections. 
 
Isolated Cholangiocytes, Hepatocytes and Biliary Cell Lines 
Large cholangiocytes were isolated by counterflow elutriation followed by immunoaffinity 
separation.10 Hepatocytes were isolated by standard collagenase perfusion.  The in vitro 
experiments were performed in human HIBEpiC and large murine cholangiocyte lines.22 
 
Evaluation of Secretin Expression in Liver and S Cells and Levels in Serum, Bile, 
and Supernatant from Cholangiocytes and S Cells 
We evaluated the expression of secretin in liver sections (4 m thick) by 
immunohistochemistry.  Sections were imaged with Leica Microsystems DM 4500 B 
Light Microscopy (Weltzlar, Germany) with a Jenoptik Prog Res C10 Plus Videocam 
(Jena, Germany).   Negative controls were included.   
Since only large cholangiocytes express secretin (see results section) and proliferate 
following BDL,23 we evaluated secretin expression (by real-time PCR and immunoblots, 
Suppl. File 1)24 in large cholangiocytes and S cells and levels by EIA kits (Phoenix 
Pharmaceuticals, Inc., Burlingame, CA) in the medium of short-term (12 hr) cultures of 
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isolated cholangiocytes and S cells (1x107 cells/ml) from normal and BDL WT mice.  We 
measured the levels of secretin secreted from basolateral and apical domains of 
cholangiocytes by plating the cell lines for 72 hr on collagen-coated filters of tissue 
culture inserts to produce a confluent monolayer.25 To determine that secretin secreted 
from cholangiocytes is bioactive, we treated large cholangiocyte lines (following serum 
starvation for 24 hr) with cholangiocyte media from normal or BDL WT mice (in the 
absence/presence of pre-incubation with secretin antibody, 0.2 g/200 l for 30 min) 
before measuring cAMP (5 min stimulation)5 levels by EIA and cell proliferation (48 hr 
stimulation) by MTS assays.24 
S cell purity was evaluated by double immunofluorescence (Suppl. File 1) for 
chromogranin A/ secretin, and chromogranin A/SR26.  We evaluated secretin levels in 
serum and bile from normal and BDL WT mice by EIA kits. 
 
Evaluation of Liver Histomorphology, IBDM and Biliary Apoptosis  
Liver histology was performed as described in Suppl. File 1.  We determined IBDM of 
small (<15 m diameter) and large (>15 m diameter) bile ducts27 and percentage of 
apoptotic cholangiocytes by terminal deoxynucleotidyltransferase biotin-dUTP nick-end 
labeling (TUNEL) kit (Apoptag; Chemicon International, Inc.) in liver sections.  
 
Effect of Secretin or Knockout of the Secretin Gene on the Proliferation and 
Expression of VEGFA/C, NGF, MicroRNA 125b and MicroRNA let7a 
Immunohistochemistry for VEGFA/C and NGF in liver sections was performed as 
described in Suppl. File 1.  We evaluated the expression of PCNA, VEGFA/C, NGF, in 
isolated cholangiocytes and microRNA 125b and microRNA let7a in isolated 
cholangiocytes and hepatocytes by real-time PCR.24 Large untransfected, vector- or 
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secretin-transfected cholangiocytes or HIBEpiC were treated with 0.2% BSA (basal) or 
secretin (10-7 M and/or 10-6 M) for 24 to 72 hr and 7 days before evaluating  proliferation 
by MTS assay24 and/or expression of PCNA, VEGFA/C, NGF, microRNA 125b and 
microRNA let7a by real-time PCR.24  We knocked down secretin expression in large 
cholangiocytes (Suppl. File 1) before measuring proliferation by MTS assays (incubation 
for 24 to 72 hr and 7 days) and expression of VEGFA/C, NGF, microRNA 125b and 
microRNA let7a (incubation for 48 hr) by real-time PCR.24   
To determine whether the expression of other microRNAs was affected by the knockout 
of secretin, we performed miScript miRNA PCR assay (SABioscience, Frederick, MD) in 
control and secretin shRNA large cholangiocytes and large cholangiocytes from normal 
and BDL WT and Sct-/- mice. Total RNAs (250 ng) were reverse-transcribed into cDNA 
with miScript II RT kit (SABioscience).  For mature microRNA expression detection, the 
cDNA was mixed with QuantiTect SYBR Green PCR Master Mix and the mixture was 
added into a 96-well RT2 microRNA PCR Assay (SABiosciences) that included primer 
pair for specific microRNA. The raw Ct was normalized to multiple housekeeping genes 
based on the established formula from the supplier. 
Large cholangiocytes were transfected with microRNA 125b/microRNA let7a inhibitors or 
anti-microRNA control; or microRNA 125b/microRNA let7a precursors or scrambled 
controls to down-regulate or overexpress microRNA 125b/microRNA let7a, before 
measuring proliferation (by MTS assays) and expression of PCNA, VEGF-A and NGF by 
real-time PCR and immunofluorescence. Transfections, real-time PCR assays and 
immunofluorescence for the expression of target genes and luciferase reporter assays 
are described in Suppl. File 1. 
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Statistical Analysis 
Data are expressed as mean ± SEM.  Differences between groups were analyzed by the 
Student’s unpaired t-test when two groups were analyzed, and by ANOVA when more 
than two groups were analyzed, followed by an appropriate post hoc test.  
Results 
Evaluation of Secretin Expression in Liver and S Cells and Levels in Serum, Bile, 
and Supernatant from Cholangiocytes and S Cells 
Normal large cholangiocytes (red arrows) express the protein for secretin; secretin 
expression increased in large BDL cholangiocytes (Figure 1A, Table 1) compared to 
normal control.  No positive staining for secretin was observed in small cholangiocytes 
and hepatocytes from normal and BDL WT mice, and cholangiocytes from normal and 
BDL Sct-/- mice (Figure 1A, Table 1).  The expression and levels of secretin were higher 
in large cholangiocytes and S cells from BDL compared to normal mice (Figure 1B-C, 
Table 2).  Secretin levels were higher in bile and serum of BDL compared to normal 
mice (Table 2).  Large cholangiocytes release secretin at both basolateral and apical 
domains (0.37±0.15 ng/1x106 cells (basolateral; n=31) and 0.074±0.01 ng/1x106 cells 
(apical; n=24)).  Incubation of a large biliary cell line with medium from normal 
cholangiocytes increased cAMP levels and proliferation of these cells; the proliferative 
effects were amplified when large cholangiocytes were incubated with the biliary 
supernatant (containing more secretin) from BDL mice (Suppl. Figure 1A-B).  Secretin-
stimulation of cAMP levels and biliary proliferation were partly decreased by pre-
incubation with a secretin-neutralizing antibody (Suppl. Figure 1A-B). The purity of S 
cells was demonstrated by positive staining for secretin/chromogranin A and 
chromogranin A/SR (Suppl. Figure 2A-B).  
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Evaluation of Liver Histomorphology, IBDM and Biliary Apoptosis 
No differences in body weight were observed among the animal groups (Suppl. Table 2).  
There was increased liver to body weight ratio in BDL compared to normal mice and 
reduced liver to body weight ratio in Sct-/- BDL compared to BDL WT mice (Suppl. Table 
2).  No changes in inflammation, necrosis and steatosis were observed in Sct-/- 
compared to WT groups (not shown). There was no difference in IBDM of small and 
large cholangiocytes between normal WT and Sct-/- mice (Figure 1D, Table 1).  There 
was increased large (green arrows) IBDM in BDL WT compared to normal mice (Figure 
1D, Table 1).  In Sct-/- BDL mice, there was reduced large IBDM (green arrows) 
compared to BDL WT mice (Figure 1D, Table 1) and enhanced biliary apoptosis (Table 
1).  In Sct-/- BDL mice there was increased IBDM of small cholangiocytes (red 
arrowheads) compared to BDL WT mice (Figure 1D, Table 1).  In normal and BDL mice 
treated in vivo with microRNA 125b or microRNA let7a Vivo-Morpholinos, there was: (i) 
reduced biliary expression of microRNA 125b and microRNA let7a in cholangiocytes 
(Suppl. Figure 3A); (ii) increased large IBDM (Figure 1E); and (iii) enhanced expression 
of VEGFA (after treatment with microRNA 125b Vivo-Morpholinos) and NGF (after 
treatment with microRNA let7a Vivo-Morpholinos) in liver sections compared to control 
mice (Suppl. Figure 3B-C; Suppl. Table 1). 
 
Effect of Secretin or Knockout of the Secretin Gene on Biliary Proliferation and 
Expression of VEGFA/C, NGF, MicroRNA 125b and MicroRNA let7a  
In large ducts, expression of VEGFA/C and NGF increased following BDL and 
decreased in Sct-/- BDL compared to BDL WT mice (Figure 2A).  In large cholangiocytes 
from Sct-/- BDL mice there was: (i) decreased expression for PCNA, VEGFA/C and NGF 
(Figure 2B); (ii) enhanced expression of microRNA 125b and microRNA let7a compared 
to BDL cholangiocytes (Figure 2C); and (iii) decreased expression of microRNA 125b 
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and microRNA let7a compared to normal cholangiocytes (Figure 2C).  Opposite to 
cholangiocytes, in hepatocytes there was increased expression of microRNA 125b and 
microRNA let7a in normal WT mice treated with secretin and BDL mice compared to 
normal WT mice and reduced expression of microRNA 125b and microRNA let7a in BDL 
Sct-/- mice compared to BDL WT mice (Suppl. Figure 4).  Since parenchymal cells do not 
express SR,28 we propose that the opposite expression pattern of microRNA 125b and 
microRNA let7a in hepatocytes is not directly linked to secretinSR axis, but may 
depend on the changes in the expression of specific transduction pathways (e.g., cAMP-
dependent signaling) that are altered by BDL and lack of secretin,11, 23 influencing 
hepatocyte functions by paracrine mechanisms.  There is also a possibility that secretin 
can interact with other G protein coupled receptors of secretin family of receptors, which 
include receptors for include vasoactive intestinal peptide receptors and receptors for 
calcitonin and parathyroid hormone/parathyroid hormone-related peptides. Secretin and 
VIP can also interact at low affinity with the VIP and SR, respectively.29 In rats, VIP binds 
to SR with similar affinity as the natural ligand, secretin, which may be a possible 
explanation for the responsiveness of hepatocytes to secretin or lack of secretin in our in 
vivo experiments.30 Our data correlate with the previous finding that hepatocyte 
proliferation during BDL, which occurs at a much lower rate than cholangiocytes, is 
limited to the replenishment of damaged hepatocytes.31 Further studies are warranted to 
elucidate mechanisms underlying the changes of microRNA 125b and microRNA let7a in 
hepatocytes in our model. 
The expression of other microRNAs involved in hepatobiliary injury and proliferation was 
altered in secretin shRNA cholangiocytes, and large cholangiocytes from normal and 
BDL WT and Sct-/- mice compared to the corresponding controls (Suppl. Figure 5). Since 
microRNA 125b and microRNA let7a were found to specifically target VEGFA and NGF 
respectively, we focused on these two microRNAs. 
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Treatment of normal WT mice with secretin: (i) increased PCNA, VEGFA (but not 
VEGFC, not shown) and NGF expression (Suppl. Figure 6A); and (ii) decreased 
microRNA 125b and microRNA let7a expression in large cholangiocytes compared to 
saline-treated mice (Figure 2D).  In vitro, secretin increased the expression of PCNA, 
VEGFA and NGF (Suppl. Figure 6B), and decreased expression of microRNA 125b and 
microRNA let7a in large cholangiocytes compared to basal (Figure 2E).   
In vitro, secretin increased proliferation of non-transfected, control vector-transfected 
and secretin shRNA-transfected large cholangiocytes and HiBEpiC cells compared to 
basal (Figure 3A-C).  We treated secretin shRNA-transfected cholangiocytes with 
secretin to demonstrate that replenishment of this hormone prevents the decrease in 
biliary proliferation (Figure 3B). In secretin shRNA-transfected cholangiocytes, there was: 
(i) decreased secretin expression and secretin secretion (Figure 4A) and reduced 
proliferation and expression of PCNA, VEGFA/C and NGF (Figure 4B-C); and (ii) 
increased expression of microRNA 125b and microRNA let7a compared to control 
cholangiocytes (Figure 4D-E).  We further determined the effect of 
downregulation/overexpression of microRNA 125b and microRNA let7a (Suppl. Figure 
7A-B) on biliary proliferation and the expression of PCNA, VEGFA and NGF (Figure 5A-
D).  The increase in biliary proliferation occurred in large cholangiocytes after 
transfection with microRNA 125b or microRNA let7a inhibitors compared to control 
(Figure 5A-C).  The increase in biliary expression of VEGFA occurred in large 
cholangiocytes after transfection with microRNA 125b inhibitors, whereas enhanced 
biliary expression of NGF was observed when cholangiocytes were transfected with 
microRNA let7a inhibitors (Figure 5B, C).  Following overexpression of microRNA 125b 
or microRNA let7a (Suppl. Figure 7B), there was reduced biliary proliferation (Figure 5B, 
D).  Overexpression of microRNA 125b significantly reduced VEGFA expression, 
whereas reduced NGF expression was observed following overexpression of microRNA 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  Glaser et al. 16 
let7a in cholangiocytes compared to control (Figure 5B, D). 
 
Identification of the Targets for MicroRNA 125b and MicroRNA let7a 
To verify that VEGF and NGF are targets of translational regulation by microRNA 125b 
and microRNA let7a in cholangiocytes, we performed studies using luciferase reporter 
constructs containing the microRNA 125b and microRNA let7a recognition sequence 
(Suppl. Figure 6C) from the 3′-UTR of VEGF and NGF inserted downstream of the 
luciferase gene. Transfection with microRNA 125b or microRNA let7a precursors 
decreased reporter activity in HiBEpiC cells. When these studies were repeated with 
reporter constructs containing random mutations in the recognition sequence, the effects 
of reporter deactivation by microRNA 125b and microRNA let7a precursors were 
abolished (Suppl. Figure 6C-D).  These findings confirmed that VEGFA and NGF are 
biologically relevant targets of microRNA 125b and microRNA let7a, respectively.  
 
Evaluation of the Interaction between Secretin and MicroRNA let7a in 
Cholangiocytes 
To demonstrate the direct interaction between secretin and microRNA let7a, the pRL-Tk 
microRNA let7a constructs, which contains microRNA let7a binding site in the 3′-UTR of 
Renilla luciferase reporter, were co-transfected with shRNA for secretin in large mouse 
cholangiocytes. The inhibition of secretin leading to the restoration of microRNA let7a 
(which binds to the 3′-UTR of Renilla luciferase reporter) significantly decreased 
luciferase activity (Suppl. Figure 6D). Thus, confirming the direct inhibitory effects of 
secretin on the expression of microRNA let7a (Suppl. Figure 6D). 
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Discussion 
This study demonstrated that secretin has autocrine and paracrine roles in the regulation 
of biliary growth during cholestasis.  We demonstrated that secretin is 
expressed/secreted by large cholangiocytes and S cells at higher levels following BDL 
compared to normal WT mice.  Higher levels of secretin were observed in serum and 
bile of BDL mice, which likely is due to enhanced secretion of this hormone by 
cholangiocytes into bile and serum, and S cells into serum.9 Knockout of the Sct gene: (i) 
reduced BDL-induced increase in large IBDM and induced a concomitant increase in 
small IBDM; (ii) decreased expression of PCNA, VEGFA/C and NGF; and (iii) increased 
expression of microRNA 125b and microRNA let7a compared to BDL WT mice.  
Treatment of normal WT mice with secretin decreased biliary expression of microRNA 
125b and microRNA let7a.  Treatment of cholangiocyte lines with secretin increased the 
expression of PCNA, VEGFA/C and NGF along with reduced expression of microRNA 
125b and microRNA let7a.  In secretin-shRNA transfected cholangiocytes there was 
reduced expression of PCNA, VEGFA/C and NGF and increased expression of 
microRNA 125b and microRNA let7a. The silencing of microRNA 125b and microRNA 
let7a enhanced biliary proliferation and VEGFA and NGF expression, whereas 
overexpression of microRNA 125b and microRNA let7a decreased biliary proliferation, 
and VEGFA and NGF expression. The direct regulation of microRNA let7a by secretin 
as well as the target verification of microRNA 125b and microRNA let7a to VEGFA and 
NGF, respectively, was confirmed by luciferase assay.  We conclude that S cells and 
cholangiocytes regulate biliary growth (by both autocrine/paracrine mechanisms) 
through the synthesis of secretin.  Local manipulation of biliary secretin expression may 
be important for the management of biliary disorders.   
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Secretin mRNA is expressed in the CNS in the cerebellum, pituitary, brainstem and 
hypothalamus.32 Limited data exists regarding the expression/synthesis of secretin in 
peripheral tissues besides S cells.33 Secretin mRNA is detected in antral and corpus 
mucosae.34 Secretin -positive cells are present in the lower part of the common bile duct 
in cholestatic patients.35 Enhanced secretin serum levels have been demonstrated in 
dogs after ligation of pancreatic or bile ducts as well as in cirrhotic patients.36, 37 The 
signaling associated with afferent pathways of parasympathetic innervation is up-
regulated following BDL and abolished by vagotomy38, 39, which may explain the 
enhanced synthesis of secretin from cholangiocytes and S cells.  
Since SR is expressed in the basolateral domain of cholangiocytes, our findings raise 
questions about the role of secretin in bile and how it interacts with SR.  Since secretin 
secreted into bile may not be eliminated in the feces, intestinal cells can reabsorb it by 
endocytosis thus reaching serum. Secretin might be an important factor for sustaining 
biliary proliferation during ductopenic diseases characterized by lack of secretin and SR 
expression and decreased bicarbonate secretion. Recent findings support the notion that 
biliary bicarbonate (stimulated by the secretin/SR axis) is a key protective mechanism for 
cholangiocytes in ductopenic states, in what has been defined as a “bicarbonate 
umbrella”. Studies have shown that such a protective layer of bicarbonate is defective in 
PBC and PSC.40, 41 In fact, microRNA 506 is up-regulated in cholangiocytes from PBC, 
binds the 3’UTR binding assay of AE2 mRNA, prevents protein translation and 
decreases biliary secretion by reduced AE2 activity.42, 43 Absence of choleretic response 
to secretin was observed in cholestatic and untreated PBC patients.44 
The stimulatory effects of secretin on cell proliferation and VEGF and NGF expression 
were due to a direct interaction with SR, since secretin effects were reproducible in an in 
vitro culture system. Interestingly, an intense proliferative reaction was observed in Sct-/- 
BDL for small cholangiocytes in vivo, thus showing an opposite trend to what we found 
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for large cells in the BDL model.11 Although the current study was not designed to 
evaluate such a phenomenon, we speculate that such an extensive ductular reaction is 
likely due to a compensatory mechanism since small cholangiocytes can proliferate and 
acquire large cholangiocyte phenotypes to repopulate damaged large ducts.45, 46 
We performed experiments aiming to determine if the effects of secretin on biliary 
proliferation and VEGFA/C and NGF expression were mediated by direct interaction with 
specific microRNAs. We have shown that several mRNA and microRNAs (VEGF, PIGF 
and TIMP-3, mircroRNA 34a and microRNA 125b) are aberrantly expressed in 
diseased/injured human and mice liver compared to normal tissue.14, 47 Specific 
microRNAs, such as microRNA let7a family members including microRNA let7a, 
regulate hepatobiliary cell proliferation and anti-inflammatory properties via repression of 
specific genes targeting downstream signaling pathways.12 Through combined analysis 
of microRNA profiling (BDL vs. control mouse liver) and bioinformatics approaches, 
microRNA 125b and microRNA let7a were chosen as the potential mediators of secretin 
regulated VEGF and NGF signaling, respectively.  Interestingly, the expression of 
VEGFC is independent of the secretin-microRNA 125b network, suggesting that 
changes in VEGFC expression are likely secondary to the increase/decrease in biliary 
proliferation mediated by secretin and other not yet identified factors.  Negative 
regulation of microRNA let7a by secretin has also been confirmed through 3'-UTR region, 
whereas the detailed mechanism of transcriptional regulation of microRNA 125b by 
secretin requires further studies.  Both microRNA 125b and microRNA let7a have been 
classified as critical modulators of cell proliferation in human liver and other organs, and 
numerous target genes were identified.48 However, studies addressing the upstream 
regulators of microRNA 125b and microRNA let7a are limited, and the mechanisms 
remain unclear. Identification of specific secretin dependent microRNA 125b-
VEGF/microRNA let7a as important regulators of cholangiocyte growth/proliferation in 
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vitro, as well as downstream signaling mechanisms underscores the essential role for 
secretin and related mRNAs/microRNAs in the mediation of hepatobiliary wound healing 
process.   
Taking into account that secretin receptors are only expressed by large cholangiocytes 
in the liver,10 up-regulated during biliary hyperplasia and down-regulated following 
cholangiocyte damage,11, 23, 28 manipulation of the secretin/SR axis can be a key 
approach for managing the growth and/or damage of large, cAMP-dependent 
cholangiocytes.  Further studies are needed to evaluate the precise contribution of S 
cells and cholangiocytes in secretin regulation of biliary homeostasis.  
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LEGENDS 
Figure 1 [A] Large normal cholangiocytes (red arrows) express secretin.  The 
expression of secretin increased in large ducts (red arrows) from BDL WT mice (see 
Table 1). Orig. magn., x20.  [B-C] The expression of secretin increased in large 
cholangiocytes and S cells from BDL compared to normal mice.  Data are mean ± SEM 
of four real-time PCR reactions and immunoblots.  *p<0.05 vs. normal WT mice.  [D] In 
BDL WT mice, there was increased large IBDM compared to control mice (green arrows).  
Knockout of the Sct gene reduced large IBDM compared to BDL WT mice (green 
arrows).  In Sct-/- BDL mice there was increased small IBDM compared to BDL WT mice 
(red arrowheads, see Table 1).  Orig. magn., x20.  [E] In mice treated in vivo with 
microRNA 125b or microRNA let7a Vivo-Morpholinos, there was increased IBDM 
compared to control mice.  *p<0.05 vs. mice treated with mismatched Morpholinos. 
 
Figure 2 [A] In large ducts, the expression of VEGF-A/C and NGF increased 
following BDL and decreased in SEC-/- BDL compared to controls.  Orig. magn., x40.  [B] 
In large cholangiocytes from SEC-/- BDL mice there was decreased expression for PCNA, 
VEGF-A/C and NGF compared to BDL cholangiocytes.  Data are mean ± SEM of four 
experiments.  *p<0.05 vs. large BDL cholangiocytes.  [C] The expression of microRNA 
125b and microRNA let7a was lower in BDL compared to normal cholangiocytes.  In 
cholangiocytes from SEC-/- BDL mice there was enhanced expression of microRNA 
125b and microRNA let7a compared to BDL WT cholangiocytes.  Data are mean ± SEM 
of four experiments.  *p<0.05 vs. normal cholangiocytes.  #p<0.05 vs. large 
cholangiocytes from WT BDL mice.  [D-E]  Secretin (both in vivo and in vitro) decreased 
expression of microRNA 125b and microRNA let7a in cholangiocytes.  Data are mean ± 
SEM of four experiments performed in purified cholangiocytes or cholangiocyte lines.  [D] 
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*p<0.05 vs. large cholangiocytes from saline-treated normal mice.  [E] *p<0.05 vs. the 
corresponding basal value. 
 
Figure 3 Secretin increased the proliferation of [A] non-transfected, [B] vector-
transfected and secretin shRNA large cholangiocytes and [C] HiBEpiC compared to the 
cell lines treated with BSA (basal). Data are mean ± SEM of six MTS assays. 
 
Figure 4  [A] In large secretin-shRNA transfected cholangiocytes, there was 
decreased secretin expression and secretin secretion compared to control 
cholangiocytes (*p<0.05).  Data are mean ± SEM of three real-time PCR reactions, three 
immunoblots and seven evaluations by ELISA kits.  [B-C] In secretin-shRNA transfected 
cholangiocytes, there was reduced proliferation and expression of PCNA, VEGF-A/C 
and NGF and [D-E] increased expression of microRNA 125b and microRNA let7a in 
different transfection time points compared to control vector-transfected cholangiocytes. 
Data are mean ± SEM of four real-time PCR reactions.  *p<0.05 vs. the corresponding 
value of control vector-transfected cholangiocytes. 
 
Figure 5 Effect of downregulation or overexpression of microRNA 125b and 
microRNA let7a (Suppl. Figure 7A-B) on biliary proliferation and expression of PCNA, 
VEGF-A and NGF.  [A, B, C] The increase in proliferation occurred in cholangiocytes 
after incubation with anti-microRNA 125b or anti-microRNA let7a inhibitors. [B, C] 
Increased expression of VEGF-A occurred in large cholangiocytes after incubation with 
anti-microRNA 125b inhibitors, whereas enhanced NGF biliary expression was observed 
when cholangiocytes were treated with anti-microRNA let7a inhibitors compared to 
control.  Following overexpression of microRNA 125b or microRNA let7a (Suppl. Figure 
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7B), there was reduced biliary proliferation [B, D].  Following overexpression of 
microRNA 125b, there was reduced VEGF-A expression, whereas reduced NGF 
expression was observed following overexpression of microRNA let7a in cholangiocytes 
[B, D).  Data are mean ± SEM of four real-time PCR reactions.  *p<0.05 vs. controls.  
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Table 1 Measurement of the % of small and large bile ducts positive for secretin, the % of 
apoptotic  
small and large bile ducts, and the % IBDM of small and large cholangiocytes. 
 
Treatment 
Secretin (%) IBDM (%) Apoptosis 
Small bile 
ducts 
Large bile 
ducts 
Small bile 
ducts 
Large bile 
ducts 
Small bile 
ducts 
Large bile 
 ducts 
WT Normal 
Not 
detected 
28.82.0 0.040.005 0.180.03 <3% <3% 
Normal Sct -/- 
Not 
detected 
ND 0.060.01 0.20.01 <3% <3% 
WT BDL 
Not 
detected 
48.02.8a 0.110.01 2.60.2b 7.40.6 15.11.5 
BDL Sct -/- 
Not 
detected 
Not 
detected 
0.510.03c 1.80.16d 10.20.6 21.01.2e 
 
Negative values correspond to <3%.  ap<0.05 vs. % of secretin-positive large ducts from normal 
WT mice.   
bp<0.05 vs. IBDM of large ducts from normal WT mice.  cp<0.05 vs. IBDM of small ducts from 
normal BDL mice.   
dp<0.05 vs. IBDM of large ducts from WT BDL mice.   
ep<0.05 vs. % apoptosis of large ducts from BDL WT mice.   
 
Table 1
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Table 2  Measurement of secretin levels in serum, bile, and supernatant from 
cholangiocytes and S cells isolated from normal and BDL WT mice. 
 
 
Groups 
 
 
Secretin levels 
in serum 
(ng/ml) 
 
 
 
Secretin levels 
in bile 
(ng/ml) 
 
 
Secretin levels 
in large 
cholangiocyte 
supernatant 
(ng/1x106 cells) 
 
 
Secretin 
levels in S 
cell 
supernatant 
(ng/1x106 
cells) 
 
WT Normal 
Mice 
 
0.56  0.09 
(n = 28) 
 
9.57  3.15 
(n = 10) 
 
1.44  0.44 
(n = 33) 
 
0.25  0.11 
(n = 6) 
 
WT BDL 
Mice 
 
2.61  0.78a 
(n = 24) 
 
76.32  28.18a 
(n = 6) 
 
19.75  5.48a 
(n = 12) 
 
36.4  10.2a 
(n = 9) 
Data are mean ± SEM. ap<0.05 vs. the value of normal WT mice. BDL = bile duct 
ligation; WT = wild-type. 
 
Table 2
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Supplemental Table 1 Measurement of the % IBDM of large 
cholangiocytes. 
 
Parameter 
Normal WT + 
microRNA 125b 
Mismatch 
Morpholino 
Normal WT + 
microRNA 125b 
Morpholino 
BDL WT +      
microRNA 125b 
Mismatch 
Morpholino 
 
BDL WT +  
microRNA 125b 
Morpholino 
 
IBDM (%) 0.210.007 0.250.005 2.20.06 
 
2.70.02* 
 
Parameter 
Normal WT +  
microRNA let7a    
Mismatch 
Morpholino 
Normal WT +   
MicroRNA let7a 
Morpholino 
BDL WT +        
microRNA let7a     
mismatch 
Morpholino 
 
BDL WT +  
microRNA let7a 
Morpholino 
 
IBDM (%) 0.230.004 0.260.005 2.30.05 
 
2.80.06* 
 
 
Data are mean ± SEM.  *p<0.05 vs. BDL mice treated with mismatch 
Morpholinos. 
 
Suppl Table 1
Click here to download Supporting Document: Table 3.docx 
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Supplemental Table 2  Measurement of body weight, liver weight and liver to body 
weight ratio in normal and BDL WT and BDL Sct -/-) mice. 
 
 
Parameter 
 
 
Normal WT 
 
 
Normal Sct -/- 
 
 
 BDL WT 
 
 
BDL Sct -/- 
 
Body weight 
(gm) 
24.80.4 
(n = 41) 
30.70.8 
(n = 16) 
20.80.3 
(n = 41) 
25.350.9 
(n = 16) 
Liver weight 
(gm) 
1.80.06 
(n = 41) 
2.50.1 
(n = 16) 
1.80.07 
(n = 41) 
1.960.08 
(n = 16) 
Liver to body 
weight ratio 
(%) 
7.30.18 
(n = 41) 
8.10.4 
(n = 16) 
8.70.3a 
(n = 41) 
7.780.3b 
(n = 16) 
 
Data are mean ± SEM.  ap<0.05 vs. liver to body weight ratio of normal WT mice.  
bp<0.05 vs. liver to body weight ratio of BDL mice.   
 
Suppl Table 2
Click here to download Supporting Document: Table 4.docx 
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Supplementary information: 
Suppl. Figure 1 In vitro effect of the medium (in the absence/presence of secretin 
antibody) of cholangiocytes from normal and/or BDL WT mice on [A] cAMP levels and [B] 
proliferation of large cholangiocytes.  Secretin-stimulation of cAMP levels and 
proliferation were partly decreased by pre-incubation with secretin antibody. *p<0.05 vs. 
basal.  #p<0.05 vs. large cholangiocytes treated with medium from BDL cholangiocytes.  
Data are mean ± SEM of four experiments. 
 
Suppl. Figure 2 Representative immunofluorescence images to colocalize: [A] 
Secretin (green staining) with chromogranin-A (red staining) and [B] secretin receptor 
(SR) (green staining) and chromogranin-A (red staining) in S cells from normal and BDL 
mice. In normal S cells, both secretin and SR (green staining) colocalize with 
chromogranin-A (red staining).  In BDL S cells, there is co-staining of secretin and SR 
with chromogranin-A, but the expression of secretin and SR is higher compared to 
normal S cells. Nuclei are stained in blue with DAPI. Bar = 200 µm. 
 
Suppl. Figure 3 [A] In normal and BDL mice treated in vivo with microRNA 125b or 
microRNA let7a Vivo-Morpholinos, there was reduced biliary expression of microRNA 
125b and microRNA let7a in cholangiocytes.  *p<0.05 vs. mismatch Morpholino treated 
mice.  [B] In liver sections from BDL mice treated in vivo with microRNA 125b Vivo-
Morpholinos there was enhanced VEGF-A expression.  [C] In liver sections from BDL 
mice treated in vivo with microRNA let7a Vivo Morpholinos there was enhanced NGF 
expression.  Orig. magn., x20. 
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Suppl. Figure 4 Evaluation of the expression of microRNA 125b and microRNA 
let7a in isolated hepatocytes.  There was increased expression of microRNA 125b and 
microRNA let7a in normal WT mice treated with secretin and BDL mice compared to 
normal WT mice, and reduced expression of microRNA 125b and microRNA let7a in 
BDL SEC-/- mice compared to BDL WT mice.  Data are mean ± SEM of four experiments. 
*# p<0.05 vs. normal WT mice.  **p<0.05 vs. BDL WT mice. 
 
Suppl. Figure 5 Altered expression of microRNAs involved in hepatobiliary injury 
and proliferation in large SEC shRNA cholangiocytes, and large cholangiocytes from 
normal and BDL WT and SEC-/- mice compared to the corresponding controls.  Real-time 
RT-PCR values represent means from triplicate measurements with multiple samples (n 
= 4–5). 
 
Suppl. Figure 6 [A] Treatment of normal WT mice with secretin increased mRNA 
expression of PCNA, VEGF-A/C and NGF in cholangiocytes.  Data are mean ± SEM of 
four real-time PCR reactions performed in cholangiocytes from four mice.  *p<0.05 vs. 
large cholangiocytes from saline-treated mice.  [B] In vitro, secretin increased mRNA 
expression of PCNA, VEGF-A/C and NGF of large cholangiocytes.  Data are mean ± 
SEM of four real-time PCR reactions.  *p<0.05 vs. the value of large cholangiocytes 
treated with BSA. [C] Targeting of VEGF and NGF 3′-UTR by microRNA 125b and 
microRNA let7a. Firefly luciferase activity was normalized to Renilla luciferase activity for 
each sample. Left: The sequences of the mutated target sites of VEGF and NGF with 
mutations to disrupt base pairing between the specific binding sites and microRNAs are 
also displayed. Right: The decreases in relative firefly luciferase with pMIR-WT-luc 
compared with the pMIR- MUT-luc constructs in microRNA 125b and microRNA let7a 
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overexpressed cells confirms that the VEGF and NGF complementary sequence in the 
3′-UTR and the genes are the direct targets of modulation by microRNA 125b and 
microRNA let7a. The data represent the mean and standard errors from three 
independent transfections. *p< 0.05 relative to respective controls.  [D] The pRL-Tk 
microRNA let7a constructs, which contains two microRNA let7a binding sites in the 3′-
UTR of Renilla luciferase reporter, were co-transfected with shRNA for secretin in large 
cholangiocytes.  The inhibition of secretin leading to the restoration of microRNA let7a 
(which binds to the 3′-UTR of Renilla luciferase reporter) caused a significant decrease 
in luciferase activity. This confirmed the direct inhibitory effects of secretin on the 
expression of microRNA let7a.  Data are mean ± SEM of four repeats.  *p<0.05 vs. 
vector-transfected cholangiocytes. 
 
Suppl. Figure 7 [A-B] microRNA expression of [A] silencing or [B] overexpression 
of microRNA 125b and microRNA let7a with anti-microRNA 125b inhibitors and anti-
microRNA let7a inhibitors or microRNA 125b precursors and microRNA let7a precursors 
on large murine cholangiocytes.  *p<0.05 vs. controls. 
 
Suppl. File 1 
List of antibodies 
The secretin polyclonal antibody (AB981) was purchased from Chemicon International 
(Temecula, CA).  The following antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA): 1) VEGF-A (JH121) mouse monoclonal antibody 
raised against full length VEGF of human origin; and 2) VEGF-C (H-190) rabbit 
polyclonal antibody raised against amino acids 230-419 of VEGF-C of human origin.  
The mouse anti-cytokeratin-19 (CK-19) antibody was purchased from Caltag 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 Suppl File Glaser, et al  
 
4
Laboratories Inc. (Burlingame, CA, USA).  The rabbit polyclonal antibody to NGF 
(ab6199) was purchased from Abcam (Cambridge, MA).   
 
Real-time PCR and Immunoblotting Analysis 
For the quantitative evaluation of mRNA expression of the selected genes, total cellular 
RNA was extracted by the RNeasy Mini Kit (Qiagen Inc., Valencia, CA), and reverse 
transcribed using the Reaction Ready™ First Strand cDNA synthesis kit (SuperArray, 
Frederick, MD).  For each reaction, we used 1.0 µg total RNA.  These reactions were 
used as templates for the PCR assays using a SYBR Green PCR master mix and 
specific primers designed against the gene for mouse secretin (NM_011328), PCNA 
(NM_01145), VEGF-A (NM_031836), VEGF-C (NM_053653), NGF (NM_013609), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_008084, housekeeping gene, 
SABiosciences), in the real-time thermal cycler (ABI Prism 7900HT sequence detection 
system). For microRNA expression study, we utilized the TaqMan microRNA assay kit 
(Applied Biosystems, Foster City, CA) with the manufacture’s protocol. Briefly, 
microRNA 125b, microRNA let7a and RNAU6 (housekeeping for microRNA 125b and 
microRNA let7a) were reverse transcribed using the TaqMan MicroRNA Reverse 
Transcription Kit, and the TaqMan microRNA real-time PCR amplification assays. For 
reverse transcription step, we used 10 ng of total RNA. The product from reverse 
transcription reaction was diluted by 1:15 for PCR amplification.   A ∆∆CT (delta delta of 
the threshold cycle) analysis was performed using normal large cholangiocytes as 
controls.  Data are expressed as fold-change of relative mRNA or microRNA levels ± 
SEM (n=6).   
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Immunoblots were performed in protein (10 µg) from whole cell lysate from purified 
cholangiocytes. Immunoblots were normalized by β-actin.  Band intensity was 
determined by scanning video densitometry using the phospho-imager, Storm 860, (GE 
Healthcare, Piscataway, NJ) and the ImageQuant TL software version 2003.02 (GE 
Healthcare, Little Chalfont, Buckinghamshire, England). 
 
Double Immunofluorescence 
For double immunofluorescence, we used smears of S cells from normal and BDL mice. 
Staining was performed by fixing cells in acetone and following washes and incubation in 
4% bovine serum albumin (BSA) in 1X Phosphate Buffered Saline Tween-20 (PBST), 
the cells were incubated with the selected primary antibodies: SR (Santa Cruz 
Biotechnology), secretin and chromogranin A (Santa Cruz Biotechnology). After one 
hour at room temperature, the cells were washed three times in PBS-T and then placed 
in the specific secondary antibodies (anti-goat Alexa Fluor 488 for SR, anti-human Alexa 
Fluor 488 for secretin and anti-rabbit Alexa Fulor 594 for chromogranin A, Invitrogen) in 
a dark room for 45 minutes. Finally, S cells were rinsed in buffer and mounted with Ultra-
Cruz mounting medium (Santa Cruz Biotechnology). To demonstrate the specificity of 
the immunoreaction, negative controls were performed without the incubation with 
primary antibody. Images were taken by DM4500B light microscopy (Leica, Wetzlar, 
Germany). 
 
Liver Histology 
Paraffin-embedded liver sections (4 µm thick, 3 sections analyzed per group) were 
stained with hematoxylin and eosin (H&E) before evaluating necrosis, steatosis, and the 
degree of portal inflammation in a coded fashion. Histology of spleen, small and large 
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intestine, kidney, stomach and heart was determined in sections stained for hematoxylin 
and eosin.  Sections were examined in a coded fashion with a BX-51 light microscope 
(Olympus, Tokyo, Japan) equipped with a camera.    
 
Immunohistochemistry for VEGF-A/C and NGF in Liver Sections 
In liver sections from WT and SEC-/- BDL mice, we evaluated the percentage of large 
bile ducts positive for VEGF-A/C and NGF.  When 0%-5% of bile ducts were positive, we 
assigned a negative score; a +/- score was assigned when 6%-10% of ducts were 
positive; and a + score was assigned when 11%-30% of bile ducts were positive.   
 
Knock-down of the Secretin Gene in Large Cholangiocytes 
The cholangiocyte line with reduced Sct gene expression was generated using 
SureSilencing shRNA (SABiosciences, Valencia, CA) plasmid for mouse Sct containing 
a marker for neomycin resistance for the selection of stably transfected cells according 
to the instructions from the vendor.  A total of 4 clones were assessed for the relative 
knockout of secretin by real-time PCR and a single clone with the greatest degree of 
knockout was selected for subsequent experiments.  The extent of secretin knockout 
was also evaluated by immunoblots, and the amount of secretin released into the 
medium.   
 
Transfections for Mature MicroRNAs 
Large murine cholangiocytes were transfected with 5 µM microRNA 125b/microRNA 
let7a inhibitors or precursors or relative controls using Lipofectamine RNAiMAX 
transfection reagent (Life Technologies, Grand Island, NY) according to manufacturer’s 
recommended protocol. Briefly, 1x105 large murine cholangiocytes were plated on 6-well 
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plates. After 24 hours, 5µl microRNA 125b/microRNA let7a inhibitors or precursors with 
controls (5 nM) were diluted in 100 µl serum-free medium and mixed with 7 µl of each 
transfection reagent (Life Technologies) pre-diluted in 93 µl serum-free medium. After 20 
minutes of incubation at room temperature, the complexes were added to the cells in a 
final volume of 1 ml of anti-biotic free medium.  
Following transfection to knockout or overexpressing microRNA 125b and microRNA 
let7a, cells were harvested after 48 hr and small RNA was isolated with mirVana™ 
microRNA Isolation Kit according to the manufacture’s instructions (Ambion).  The 
expression of specific mature microRNAs was confirmed by real-time PCR analysis 
using TaqMan Human MicroRNA Assay kit (Applied Biosystems, Foster City, CA) with 
the TaqMan Universal PCR Master Mix reagent kit (Applied Biosystems) (details are 
shown above in real-time PCR section).  Normalization was performed using RNA U6 as 
housekeeping RNA. To demonstrate that microRNA 125b and microRNA let7a regulates 
VEGF and NGF and biliary proliferation in large murine cholangiocytes, we measured by 
real-time PCR and immunofluorescence the expression of PCNA, VEGF-A and NGF 
after the confirmation of knocking down or overexpression of microRNA 125b and 
microRNA let7a. 
Immunofluorescence for VEGF, NGF and PCNA was performed after 72 hours as 
follows.  Cells were cultured to confluency on 1.5% collagen-coated culture chambers 
(Chemicon International). Monolayers were washed twice and fixed in 100% ice-cold 
acetone for 10 minutes, then blocked in PBS containing 2% rabbit serum and 5% mouse 
serum for 1 hour at room temperature before incubation with primary antibodies, mouse 
anti-VEGF-A and anti-NGF (1:100), and rabbit anti–PCNA (1:100) overnight at 4°C 
followed by secondary fluorescein isothiocyanate–conjugated anti-rabbit (1:200) for 1 
hour at room temperature. After 3 washes, monolayers were mounted on glass slides 
with ProLong antifade mounting medium with DAPI (Molecular Probes). Images were 
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viewed and captured using Leica TCS SP5 confocal microscope system (Wetzlar, 
Germany). 
 
Luciferase Reporter Assay 
HIBEpiC were co-transfected with 1 µg of firefly luciferase reporter plasmid and 100 
nmol of microRNA precursor (pre-microRNA 125b and pre-miR-microRNA let7a 
respectively), or control pri-microRNA using DhamarFECT (Dharmacon, Thermofisher, 
Lafayette, CO) according to the manufacture’s instructions.  Next, cells were assayed 
using luciferase assay kits (Promega) after 72 hr of transfection. Each transfection 
experiment was performed in triplicate.  Similarly, to demonstrate the regulation of 
secretin to microRNA let7a, we plated large murine cholangiocytes into 6-well plates.  
After 24 hours, the pRL-TK microRNA let7a which include two binding sites of microRNA 
let7a after the Renilla luciferase or the pRL-TK control were co-transfected with shRNA 
of secretin or shRNA control using DhamarFECT (Dharmacon, Thermofisher) according 
to the manufacture’s instructions.  After 48 hr, cells were lysed with passive lysis buffer 
(Promega).  Aliquots of lysates were analyzed by dual luciferase reporter assay system.  
All signals from Renilla luciferase sensors were first normalized with that from firefly 
luciferase. The normalized values were re-normalized with the specific value of signals 
from the control plasmid. 
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